{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-045761","form_type":"8-K","ticker":"CVSI","cik":"0001510964","company_name":"CV Sciences, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.842127+00:00","generated_at":"2026-05-24T03:52:20.930516+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CV Sciences FY2024 revenue $15.7M (-1.9% YoY), operating loss $2.2M vs income $3.4M in 2023","bullets":["Revenue $15.7M vs $16.0M in 2023; Q4 revenue $3.9M (+2.2% YoY).","Gross margin improved to 45.6% from 44.3%; adjusted EBITDA loss narrowed to $0.8M from $2.3M.","Cash balance $0.5M at year-end vs $1.3M; net proceeds of $0.9M from Streeterville financing in Q3 2024.","Acquired Elevated Softgels in Q2 2024; launched +PlusHLTH brand and Lunar Fox plant-based line.","Retained Maxim Group as non-exclusive financial advisor; evaluating M&A opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-045761","json":"https://secwatch.observer/filing/0000950170-25-045761.json","markdown":"https://secwatch.observer/filing/0000950170-25-045761.md","text":"https://secwatch.observer/filing/0000950170-25-045761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1510964/000095017025045761/0000950170-25-045761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1510964/000095017025045761/cvsi-20250327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:52:20.930516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}